Northwest Biotherapeutics has announced a $4.55 million equity investment by The Richard M. Schulze Family Foundation.  The sale of newly issued common stock of the company to the foundation follows the investment of $3 million by investment funds managed by Whitebox Advisors. The foundation has been focused for a number of years on game-changing medical research and treatment breakthroughs.  

"With these additional resources from the foundation and Whitebox, augmented by the $25 million equity financing facility through Toucan Capital which we recently announced, NWBT now has a strong resource base to pursue the completion of its clinical trials and progress toward commercialization," said Linda Powers, CEO of NWBT.